The story · written by gpt-6,
Panama’s Law 242 of 13 October 2021 created a framework for medicinal and therapeutic cannabis. It began a licensing and regulatory process, rather than immediately giving patients a pharmacy where they could obtain a cannabis medicine. Years separated that legal framework from the first specialist pharmacy.[1][2][3]
A framework awaiting suppliers
The law provided for authorised manufacture and regulated handling of cannabis derivatives. But on 22 July 2023 the health ministry said that selection of manufacturing licensees was still under way. Cannabis-derived products were not authorised for distribution or sale in Panama. The ministry also warned that handling outside the medical law remained subject to the Penal Code.[2]
That notice matters when dating access: the existence of a statute in 2021 did not mean a patient could buy a product through an operating licensed channel in 2023.[2]
New rules and a first pharmacy
Executive Decree 6 of 4 April 2025 revised the rules implementing Law 242. The drug directorate describes its purpose as supervised access for therapeutic, medical, veterinary, scientific and research uses, alongside the rules for controlled substances.[1]
On 22 January 2026 a specialist cannabis pharmacy opened, and the ministry reported seven commercial licences. Those developments belong to the later implementation of the law, rather than to its original enactment.[3]
CBD and patient registration
The drug directorate’s published product register lists Cannapharma cannabidiol products dated 22 January 2026. That CBD listing does not establish that controlled THC medicines were being dispensed.[4]
On 2 June the ministry announced approved forms for patients and authorised companions. A qualified doctor must certify the treatment, including diagnosis, dose and duration. Certification starts the registration process; after verification and approval, the patient receives a card for obtaining medicines at authorised pharmacies. The announcement said the forms and instructions would be published shortly.[5]
How the index records access
The 2021 event remains in the history as an enabling law. The 2023 sales prohibition, first pharmacy and registration announcement show the subsequent steps.[2][3][5]
Panama’s profile keeps medical status limited and access at zero. A pharmacy opening and a CBD register cannot establish the working THC medicine route that the earlier score increase had assumed.[3][4]
Listed for context. No score change is recorded for Panama here.
References
- DNFD — Executive Decree 6 of 4 April 2025, regulating Law 242 of 2021archived
- MINSA — cannabis-product distribution and sale remain prohibited (22 July 2023)archived
- TVN — first specialist pharmacy and seven commercial licences (22 January 2026)archived
- DNFD — medical cannabis product register (reviewed 25 October 2026)archived
- MINSA — patient certification and registration forms (2 June 2026)archived
Checked. The date and the event were compared with a source that was read.